Furthermore, in melanoma, LOF mutations in JAK1 and JAK2 have been linked to the loss of PD-L1 expression in the TME resulting from dampened tumor-inherent IFN signaling, which might contribute to poor patient response to checkpoint inhibitors [161]. The gene discussed is IFNA1; the disease is melanoma.